Lupin, Boehringer Ingelheim to co-market two anti-diabetic drugs

The two companies will collaborate to introduce two new oral anti-diabetics drug in the Indian market. Anti-diabetic drugs Gibtulio Met and Ajaduo were recently approved by the Indian drug regulator.

Gibtulio Met and Ajaduo are patented in India and approved by the Drugs Controller General of India. The drugs will be simultaneously co-marketed by the German pharma major Boehringer Ingelheim and Lupin under different brand names, across the country.

The combination drug Gibtulio Met (Empagliflozin +Linagliptin) is a approved combination of a SGLT-2 inhibitor and DPP4 inhibitor. It is indicated for lowering blood sugar levels and help treat multiple pathophysiological issues in type 2 diabetes. The second drug Ajaduo (Empagliflozin + Metformin) is a combination that can be prescribed to newly diagnosed patients with high baseline HbAlc levels and helps manage cardiac complications in type 2 diabetes patients with heart disease.

Indian oral anti-diabetic market is valued at Rs. 83,340 million and is growing at 11.21 per cent, according to IMS MAT April 2018 data.

On Wednesday at 12:53 hours, the stock of Lupin Limited was trading at Rs. 905.55 per share, up by 0.26 per cent, while the benchmark index BSE Sensex was at 36,257.07, up by 17.45 points or 0.05 per cent.